BofA analyst Tazeen Ahmad downgraded Cyteir Therapeutics to Neutral from Buy with a price target of $2, down from $4.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CYT: